期刊文献+

高纯度尿促性素和普通尿促性素促排卵效果 被引量:8

Efficacy of highly purified hMG and ordinary hMG among Chinese women undergoing ovarian induction
下载PDF
导出
摘要 目的比较高纯度尿促性素(humanmenopausalgonadotropin,hMG)和国产普通hMG在接受诱发排卵后行宫腔内人工授精或指导同房治疗的患者中的效果和安全性。方法2004年7月至2005年3月在3个生殖中心选择符合条件的219例不育妇女进行随机分组促排卵治疗,高纯度hMG组108例,普通hMG组111例。观察主要疗效指标排卵率;次要疗效指标临床妊娠率、破裂卵泡数目、注射hMG日血清E2峰浓度、药物应用时间和药物总剂量;安全性评价指标不良事件发生率。结果普通hMG和高纯度hMG排卵率分别为93.0%(93/100)和91.0%(91/100),临床妊娠率为12.4%(12/100)和20.0%(20/100),破裂卵泡数目为(1.5±1.4)个和(1.2±0.9)个,血E2峰浓度为(896.5±911.9)pmol/L和(699.0±618.5)pmol/L,用药时间为(11.6±3.7)d和(11.6±4.1)d,用药剂量为(1147.5±46.8)IU和(1280.6±646.0)IU,两者疗效及安全性评价指标的比较,差异无显著性(P>0.05)。结论高纯度hMG的促排卵治疗和国产普通hMG一样有效而安全。 Objective To compare the efficacy and safety ot highly puritied hMG and ordinary hMG among Chinese women undergoing ovarian induction in intrauterine insemination (IUI) or timed intercourse (TI). Methods Between July 2004 and March 2005, infertile female subjects were recruited at 3 Reproductive Medical Centers in China. A total of 219 women were randomized into two groups (108 in highly purified hMG, 111 in ordinary hMG) for ovarian induction. The primary efficacy variable was the ovulation rate and the secondary efficacy variables included the clinical pregnancy rate, the number of ovulated follicles, serum concentration of estradiol on the day of hCG injection, the duration of stimulation and the total dose of ordinary hMG used. The main safety parameters were the incidence of adverse events (AE). Results No significant differences were found between the ordinary hMG and highly purified hMG group in the ovulation rate (93.0 % versus 91.0 %), the clinical pregnancy rate (12.0%versus 20.0 %), the number of ovulated follicles (1.5±1.4 versus 1.2±0.9), serum concentration of estradiol on the day of hCG injection (816.5±911.9 pmol/L versus 699. 0±618.5 pmol/L ), the duration of stimulation (11.6±3.7 versus 11.6±4.1 d) and the total dose of ordinary hMG used (1147.5±468.3 versus 1280. 6±646.0 IU). No differences were seen in the main safety parameters (P〉0.05). Conclusion highly purified hMG is as effective and safe as ordinary hMG in ovarian induction.
出处 《中国生育健康杂志》 2005年第4期205-208,共4页 Chinese Journal of Reproductive Health
关键词 高纯度 尿促性素 促排卵作用 HMG 宫腔内人工授精 Human menopausal gonadotropin Ovarian induction Intrauterine insemination
  • 相关文献

参考文献11

  • 1Filieori M, Cognigni GE. Roles and novel regimen of luteinizing hormone and follicle-stimulating hormone in ovulation induction. J Clin Endoerinol Metab, 2001, 86: 1437-1441.
  • 2The european and israeLi study group on highLy purified menotropin versus recombinant follicle—stimulating hormone.Efficacy and safety of highly purified menotropin versus recombinant follicle—stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized,comparative trial.Fertil Steril,2002,78:520—528.
  • 3Kilani Z,DakkakA,Ghunaims,et a1. A prospective,randomized,controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI:ovarian response and clinical outcomes.Hum Reprod,2003,18;1194—1199.
  • 4Lloyd,Kennedy R,Hutchinson J A,et a1.Economic evaluation of highly purified menotropin compared with recombinant follicle—stimulating hormone in assisted reproduction.Fertil Steril,2003,80:1108—1113.
  • 5Golan A,Ronel R,Herman A,et a1.Ovarian hyperstimulation syndrome:an update review.Obstet Gynecol Surv,1989,44(6):430—440.
  • 6Schoolcraft WB,Gardner Dk,Lane M,et a1.Blastocyst culture and transfer:analysis of results and parameters affecting outcome in two in vitro fertilization programs.Fertil Steril,1999,72:604—609.
  • 7Filicori M,Cognigni GE,Taraborrellis,et a1.Luteinizing hormone activity supplementation enhances follicle—stimulating hormone efficacy and improves ovulation induction outcome.J CLin Endocrinol Metab,1 999,84:2659—2663.
  • 8Fleming R,Chung CC,yates RM,et al.Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotropin,dependent upon the route of administration and endogenous luteinizing hormone activity.Hum Reprod,1996,11:1854—1858.
  • 9Agrawal R,Conwar GS,Engmann L,et a1.Implications of using follicle stimulating hormone preparations depleted of Luteinizing hormone to achieve follicular growth in in vitro fertilization.Gynecol Endocrinol,1998,12:9-15.
  • 10Westergaard LG,Laursen SB,Andersen Y,et al.Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction.Hum Reprod,2000,15:1003—1008.

同被引文献87

引证文献8

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部